



# heligenics

ENABELING PRECISION MEDICINE

# the problem

## THE CLINICAL SIGNIFICANCE OF MOST GENETIC VARIANTS IS UNKNOWN


### market share

Genetic testing companies are fighting for market share



### failure

Diagnostic yield for genetic tests is low  
**10-30%**




### patients

Genetic tests do not have broad scope because the impact of most variants is unknown




# one size does not fit all

Percentage of the patient population for which a particular drug is NOT effective



# emergence of precision medicine



- 46% of total recent approvals
- One or few genetic markers

# the solution

100% PRECISION CARE WITH  
GUESS-FREE ADVANCED  
GENETICS


## WE OFFER

- *Improve diagnostic yield with gene mutation libraries*
- *Functional experimental data for training deep learning algorithms*





# Gene Panel Diagnostics


## Single Mutation Diagnostic Yield




## GML Gene Panel Diagnostic Yield



 Disease, but lack Single Mutation Biomarker

 Disease with Single Mutation Biomarker

 Disease with Gene Panel Biomarker

Better Diagnostic Yield



EXAMPLE OF


# Lynch Syndrome *MSH2*

**problem**

- Diagnosis of Lynch Syndrome
- E483G and L173P are pathogenic missense variants
- GML with 1,700 new loss of function pathogenic mutations (VUSs)

**solution**

A *MSH2* GML that uses all *MSH2* loss of function variants for diagnosis



OUR UNIQUE ADVANTAGE

# GigaAssay

- Covers >95% of all single amino acid substitutions (variants)
- Can test variants with any human reporter systems for any cellular function: transcription, cell division, cell death, cell signaling, ....
- High throughput – 100,000s of cell measurements





<https://heligenics.com/>



<https://www.linkedin.com/company/heligenics-inc/?viewAsMember=true>



[@heligenics](https://twitter.com/heligenics)